Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOVANTRONE vs CLOFARABINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.
Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.
Treatment of acute nonlymphocytic leukemia (ANLL) in adults (in combination with other agents),Treatment of advanced hormone-refractory prostate cancer (in combination with corticosteroids),Treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (to reduce neurologic disability and frequency of clinical relapses)
Treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric patients aged 1 to 21 years,Off-label: Treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.
52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.
Terminal elimination half-life: 23-215 hours (mean ~37 hours). The long half-life reflects extensive tissue distribution and slow elimination, allowing weekly dosing.
Terminal elimination half-life: 5.2 hours (range 4-6 hours) in adult patients; clinically, this supports a 5-day continuous infusion schedule
Mitoxantrone is extensively metabolized in the liver via oxidation and conjugation, primarily by cytochrome P450 enzymes, forming inactive metabolites. Elimination is mainly via the hepatobiliary system with fecal excretion; small amounts are excreted renally.
Hepatic; primarily metabolized by deamination via cytidine deaminase to 6-ketoclofarabine, a major metabolite. Also undergoes phosphorylation intracellularly. CYP450 involvement is minimal.
Primarily hepatic (biliary/fecal) elimination: ~25% as unchanged drug and metabolites in feces over 5 days; renal excretion accounts for ~11% (6-11%) as unchanged drug. Less than 10% excreted unchanged in urine.
Renal: 49-60% as unchanged drug; biliary/fecal: minimal (<1%)
~78% bound to plasma proteins (primarily albumin).
47% bound to plasma proteins (primarily albumin)
Mean Vd: 8-22 L/kg (range 6-44 L/kg). Large Vd indicates extensive tissue distribution and binding to intracellular components.
Vd: 14.6 L/kg (range 10-20 L/kg); indicates extensive extravascular distribution and tissue binding
Intravenous: 100% (only route of administration). Oral bioavailability is <5% and not clinically relevant; no other routes used.
IV: 100% (only IV route); oral: not approved
No dose adjustment required for GFR >50 m L/min. For GFR 10-50 m L/min: administer 75% of normal dose. For GFR <10 m L/min: administer 50% of normal dose.
Clcr ≥ 60 m L/min: no adjustment; Clcr 30-59 m L/min: reduce dose to 39 mg/m^2; Clcr < 30 m L/min: not recommended (no data).
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25%. Child-Pugh Class C: reduce dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25% (monitor toxicity); Child-Pugh C: not recommended (no data).
Safety and efficacy not established; not recommended for pediatric use.
52 mg/m^2 intravenously over 2 hours daily for 5 days every 28 days (same as adult dosing per body surface area; safety and efficacy established in pediatric patients 1 year and older).
Monitor cardiac function closely due to increased risk of cardiotoxicity. Higher risk of myelosuppression; consider lower initial doses based on renal function (see renal adjustment).
No specific dose adjustment based solely on age; monitor renal function closely due to increased risk of nephrotoxicity; use same dosing as adults with renal adjustment as per GFR.
1. Mitoxantrone should be administered under the supervision of a physician experienced in the use of cancer chemotherapy agents. 2. Cardiac toxicity, including congestive heart failure, can occur and may be cumulative; risk increases with prior anthracycline use, mediastinal radiotherapy, pre-existing cardiac disease, or concomitant cardiotoxic drugs. 3. Secondary acute myeloid leukemia (AML) has been reported in patients treated with mitoxantrone-containing regimens. 4. Severe myelosuppression will occur.
Clofarabine causes severe bone marrow suppression, including neutropenia, anemia, thrombocytopenia, and increased risk of infection. Hemorrhage and severe infections have been reported. Monitor blood counts regularly.
Cardiotoxicity: Monitor left ventricular ejection fraction (LVEF) before and during therapy; cumulative dose limit of 140 mg/m² in multiple sclerosis patients.,Myelosuppression: Severe neutropenia, thrombocytopenia, and anemia; monitor complete blood counts regularly.,Secondary malignancies: Increased risk of AML and myelodysplastic syndrome.,Hepatic impairment: Dose reduction may be necessary; monitor liver function.,Renal impairment: Use with caution; adjust dose if severe.,Immunosuppression: Increased risk of infections; avoid live vaccines.,Pregnancy: Can cause fetal harm; advise effective contraception.,Extravasation: Can cause tissue necrosis; administer via IV with care.
1) Myelosuppression: monitor CBCs; dose adjustment may be needed. 2) Infections: increased susceptibility. 3) Hemorrhagic cystitis: may occur; manage with hydration and monitoring. 4) Hepatic toxicity: monitor liver function tests; dose reduction in hepatic impairment. 5) Renal toxicity: monitor renal function; dose adjustment for creatinine clearance <60 m L/min. 6) Tumor lysis syndrome: hydrate and use prophylactic allopurinol. 7) Systemic inflammatory response syndrome (SIRS): monitor for signs; discontinue if occurs.
Hypersensitivity to mitoxantrone or any component of the formulation,Significant pre-existing bone marrow suppression (e.g., baseline neutrophil count <1500/mm³, platelet count <50,000/mm³),Patients with clinically significant cardiac disease (e.g., myocardial infarction within 6 months, unstable angina, severe heart failure)
Hypersensitivity to clofarabine or any component of the formulation; severe hepatic impairment (Child-Pugh class C); severe renal impairment (creatinine clearance <30 m L/min).
No known food interactions. Maintain adequate hydration to prevent tumor lysis syndrome. Avoid grapefruit juice as it may theoretically interfere with metabolism, though not clinically significant.
Grapefruit and grapefruit juice may affect liver enzymes and should be avoided. No specific food restrictions, but avoid alcohol due to potential hepatotoxicity. Maintain adequate hydration; no other known food interactions.
Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major congenital malformations. Second and third trimester exposure may cause fetal growth restriction, myelosuppression, and cardiac toxicity. Use during pregnancy is contraindicated unless the potential benefit outweighs the risk.
Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malformations including neural tube defects, skeletal anomalies, and cardiovascular defects. Second and third trimester exposure may cause fetal myelosuppression, intrauterine growth restriction, and premature delivery.
Mitoxantrone is excreted into human breast milk; the milk-to-plasma ratio is not well characterized. Due to the potential for serious adverse reactions in nursing infants, including immunosuppression and cardiotoxicity, breastfeeding is contraindicated during therapy and for at least 1 month after the last dose.
It is unknown whether clofarabine is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 1 week after the last dose. M/P ratio is not available.
No specific dose adjustments are established for pregnancy. However, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Dose adjustment based on body surface area and close monitoring for toxicity are recommended. Use lowest effective dose and consider alternative therapies if possible.
No specific pharmacokinetic studies have been conducted in pregnant women. Dose adjustments based on pregnancy-induced physiologic changes (increased plasma volume, renal clearance) are not established. Use with caution; the lowest effective dose based on tolerability and clinical response is recommended. Close monitoring for toxicity is essential.
Mitoxantrone is a topoisomerase II inhibitor and anthracenedione; cumulative lifetime dose should not exceed 140 mg/m² due to dose-dependent cardiotoxicity. Pre-treatment LVEF must be assessed and monitored regularly. Administration requires cardiac monitoring during infusion due to risk of arrhythmias.
Clofarabine is a purine nucleoside antimetabolite used primarily in pediatric relapsed or refractory acute lymphoblastic leukemia (ALL). It is associated with significant myelosuppression; monitor absolute neutrophil count and platelets closely. Capillary leak syndrome and systemic inflammatory response syndrome (SIRS) are rare but serious adverse effects; consider prophylactic corticosteroids. Hepatic veno-occlusive disease (VOD) has been reported, especially in patients with prior stem cell transplant. Administer with adequate hydration and monitor for tumor lysis syndrome.
Report any shortness of breath, cough, or swelling of ankles/feet immediately as these may indicate heart problems.,Urine may turn blue-green for 24-48 hours after infusion; this is harmless.,Avoid live vaccines during treatment and for 6 months after.,Use effective contraception during and for at least 4 months after therapy due to risk of fetal harm.,Notify your doctor if you experience easy bruising, bleeding, fever, or signs of infection.
Clofarabine is a chemotherapy drug that may lower your blood cell counts, increasing risk of infection, bleeding, and fatigue.,Report any signs of infection (fever, chills, sore throat), unusual bleeding or bruising, or shortness of breath immediately.,Drink plenty of fluids (8-10 glasses per day) to prevent kidney problems and tumor lysis syndrome.,Avoid live vaccines and close contact with people who have recently received oral polio vaccine.,Use effective contraception during treatment and for at least 6 months after the last dose.,Do not breastfeed while taking clofarabine.,You may experience nausea, vomiting, or diarrhea; your doctor can prescribe medications to manage these symptoms.
No interactions on record
"Clofarabine, a purine nucleoside antimetabolite used in hematologic malignancies, may reduce the metabolism of Eltrombopag, a thrombopoietin receptor agonist, via inhibition of UDP-glucuronosyltransferase (UGT) enzymes, particularly UGT1A1 and UGT1A3. This leads to increased systemic exposure of Eltrombopag, potentially elevating the risk of hepatotoxicity (e.g., elevated liver enzymes) and other adverse effects such as thrombosis. Clinical outcomes may include exacerbated liver injury, which is particularly concerning in patients with pre-existing hepatic impairment or those receiving other hepatotoxic agents."
"Concurrent use of clofarabine and mecamylamine may synergistically increase the risk of severe hypotension and syncope. Clofarabine is a purine nucleoside analog that can cause capillary leak syndrome and hypotension, while mecamylamine is a ganglionic blocker that inhibits sympathetic outflow, leading to orthostatic hypotension. The combined hypotensive effects may result in profound blood pressure reduction, dizziness, and potential falls, particularly in patients with impaired cardiovascular function."
"The combination of clofarabine and nifedipine may increase the risk of cardiotoxicity, particularly QT interval prolongation and left ventricular dysfunction. Clofarabine has been associated with pericardial effusion and cardiac tamponade, while nifedipine, a calcium channel blocker, can cause hypotension and reflex tachycardia, potentially compounding hemodynamic stress in patients with compromised cardiac function. Clinical outcomes may include arrhythmias, heart failure exacerbation, or sudden cardiac death, especially in patients with preexisting cardiovascular risk factors."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NOVANTRONE vs CLOFARABINE, answered by our medical review team.
NOVANTRONE is a Antineoplastic Agent that works by Mitoxantrone is a synthetic anthracenedione derivative that intercalates with DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA and RNA synthesis. It also disrupts DNA repair and replication, and has immunosuppressive effects through inhibition of B cell, T cell, and macrophage function.. CLOFARABINE is a Antineoplastic Agent that works by Clofarabine is a purine nucleoside antimetabolite that inhibits DNA synthesis by reducing intracellular deoxynucleotide triphosphate pools via inhibition of ribonucleotide reductase, and by terminating DNA chain elongation through incorporation into DNA, leading to apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOVANTRONE and CLOFARABINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOVANTRONE is: 12 mg/m2 IV over 5-15 minutes once daily on days 1-3 of a 28-day cycle, or as a single dose of 12-14 mg/m2 IV every 21 days. For acute nonlymphocytic leukemia, 12 mg/m2 IV daily for 3 days with cytarabine.. The standard adult dose of CLOFARABINE is: 52 mg/m^2 intravenously over 2 hours daily for 5 consecutive days, repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOVANTRONE and CLOFARABINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOVANTRONE is classified as Category C. Mitoxantrone is teratogenic in animals and is classified as Pregnancy Category D. First trimester exposure is associated with increased risk of spontaneous abortion and major conge. CLOFARABINE is classified as Category C. Clofarabine is embryotoxic and teratogenic in animal studies. In humans, it is classified as Pregnancy Category D. First trimester exposure is associated with major congenital malf. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.